Expression Analysis Enters into a Partnership with Complement Genomics to Offer Genomic Services in UK
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Expression Analysis enters into a partnership with Sunderland based Complement Genomics Ltd. to offer its genomic services to the UK market.
Expression Analysis, Inc. has entered into a partnership with Sunderland based Complement Genomics Ltd. to offer its genomic services to the UK market. By partnering with an established company, Expression Analysis will gain access to clients beyond its primary market in the US.
The Geneblitz® unit offers molecular services to pharmaceutical companies, governmental agencies, universities and research institutes. The partnership will give Expression Analysis access to these clients and will allow both companies to expand their service offerings.
“The partnership with Geneblitz® provides us an established presence in the United Kingdom, with an experienced service provider who operates with the same philosophy and similar quality standards and platforms,” stated Steve McPhail, President and CEO of Expression Analysis. Geneblitz® will focus its efforts on Genome-Wide Association studies which have become an increasingly larger part of our business, continued McPhail.
“Expression Analysis is an industry leader with a great reputation in the field of genomic services and our decision to partner with them was not a difficult one,” said Louise Allcroft, Chief Executive Officer of Complement Genomics Ltd. “By combining our experience, scientific leadership and high-throughput capabilities, we will be able to help meet the needs of the extensive pharmaceutical and biotechnology infrastructure in the United Kingdom.”
Expression Analysis, Inc. has entered into a partnership with Sunderland based Complement Genomics Ltd. to offer its genomic services to the UK market. By partnering with an established company, Expression Analysis will gain access to clients beyond its primary market in the US.
The Geneblitz® unit offers molecular services to pharmaceutical companies, governmental agencies, universities and research institutes. The partnership will give Expression Analysis access to these clients and will allow both companies to expand their service offerings.
“The partnership with Geneblitz® provides us an established presence in the United Kingdom, with an experienced service provider who operates with the same philosophy and similar quality standards and platforms,” stated Steve McPhail, President and CEO of Expression Analysis. Geneblitz® will focus its efforts on Genome-Wide Association studies which have become an increasingly larger part of our business, continued McPhail.
“Expression Analysis is an industry leader with a great reputation in the field of genomic services and our decision to partner with them was not a difficult one,” said Louise Allcroft, Chief Executive Officer of Complement Genomics Ltd. “By combining our experience, scientific leadership and high-throughput capabilities, we will be able to help meet the needs of the extensive pharmaceutical and biotechnology infrastructure in the United Kingdom.”
